Aldeyra Therapeutics Launches the Aldeyra Registry for Patients with Sjögren-Larsson Syndrome
"We are delighted to collaborate with the SLS patient community on the critical task of uniting patients affected by this rare but serious disease with no
SLS is caused by genetic mutations in Fatty Aldehyde Dehydrogenase (FALDH), an enzyme that metabolizes long-chain aldehydes. The primary day-to-day complaint of SLS patients and their caregivers is ichthyosis: severely dry, itchy skin. Patients with this debilitating disease are consistently disturbed by their dermal symptoms, which affect most of the body surface, and often excoriate their skin by scratching. There is currently no
"The Aldeyra Registry is an important effort that can ultimately help all SLS patients. I commend Aldeyra for taking a leadership role and partnering with the SLS and rare disease patient communities," said Dr.
Patients, caregivers, and physicians that register will receive information about Aldeyra's therapeutic development program in SLS, as well as opportunities to participate in clinical trials. Visit the Aldeyra Registry for SLS at: www.aldeyraregistry.com
About
Sjögren-Larsson Syndrome (SLS)
Sjögren-Larsson Syndrome is a rare inborn error of aldehyde metabolism caused by mutations in fatty acid aldehyde dehydrogenase, leading to elevated toxic fatty aldehyde levels that are thought to contribute to severe ichthyosis (scaly, thickened, dry skin), neurological disorders, and retinal disease. There is no therapy for SLS that has been approved by the
Safe Harbor Statement
This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including but not limited to statements regarding Aldeyra's plans for its product candidates, expected development timelines and potential benefits of the Aldeyra Registry for SLS. In some cases, you can identify forward-looking statements by terms such as "may," "might," "will," "objective," "intend," "should," "could," "can," "would," "expect," "believe," "anticipate," "project," "target," "design," "estimate," "predict," "potential," "aim," "plan" or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Aldeyra is at an early stage of
development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Aldeyra's forward-looking statements include, among others, the timing of enrollment, commencement and completion of Aldeyra's clinical trials, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; the ability to obtain and maintain regulatory approval to conduct clinical trials and to commercialize Aldeyra's product candidates, and the labeling for any approved products; the scope, progress, expansion, and costs of developing and commercializing Aldeyra's product candidates; the size and growth of the potential markets for Aldeyra's product candidates and the ability to serve those markets; Aldeyra's expectations regarding Aldeyra's expenses and
revenue, the sufficiency of Aldeyra's cash resources and needs for additional financing; the rate and degree of market acceptance of any of Aldeyra's product candidates; Aldeyra's expectations regarding competition; Aldeyra's anticipated growth strategies; Aldeyra's ability to attract or retain key personnel; Aldeyra's ability to establish and maintain development partnerships; Aldeyra's expectations regarding federal, state and foreign regulatory requirements; regulatory developments in
In addition to the risks described above and in Aldeyra's other filings with the
Corporate Contact:
Tel: +1 781-761-4904 ext. 205
Email Contact
Investor Contact:
Tel: 339-970-2843
Email Contact
Media Contact:
781-591-3443
Email Contact
Source:
News Provided by Acquire Media